Advertisement
Singapore markets close in 16 minutes

  • Straits Times Index

    3,275.40
    -12.35 (-0.38%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,106.75
    +27.89 (+0.35%)
     

  • Bitcoin USD

    64,393.46
    +551.05 (+0.86%)
     

  • CMC Crypto 200

    1,388.99
    -7.54 (-0.54%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,359.30
    +16.80 (+0.72%)
     

  • Crude Oil

    83.77
    +0.20 (+0.24%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,574.18
    +4.93 (+0.31%)
     

  • Jakarta Composite Index

    7,067.85
    -87.45 (-1.22%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021

Amicus Therapeutics, Inc.
·1-min read

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May:

  • Bank of America 2021 Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. E.T.

  • UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 10:00 a.m. E.T.

A live audio webcast of each presentation can be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

ADVERTISEMENT

CONTACT:

Investors:
Andrew Faughnan
Sr. Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G